Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST02
- Development stage
- Phase 1
- Lead developer
- Biosyngen
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BST02 is a novel adoptive immune cell therapy based on the expansion of a patient's own tumor-infiltrating lymphocytes (TILs). It is designed for the treatment of all forms of liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma. Unlike traditional TIL therapies, BST02 does not require high doses of interleukin-2 and can be cryopreserved, which simplifies logistics and broadens accessibility. BST02 represents the first TIL cell therapy to reach clinical development for liver cancer globally. The drug is currently being evaluated in phase 1/2 clinical trials to assess its safety, tolerability, and initial efficacy in patients with advanced or metastatic liver cancer who have failed or are unsuitable for standard systemic therapies.
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on BST02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST02.